News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
653,523 Results
Type
Article (49812)
Company Profile (233)
Press Release (603460)
Multimedia
Podcasts (179)
Webinars (26)
Section
Business (178937)
Career Advice (2612)
Deals (32986)
Drug Delivery (149)
Drug Development (79823)
Employer Resources (171)
FDA (16687)
Job Trends (13830)
News (317115)
Policy (32863)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2453)
Academic (1)
Accelerated approval (38)
Adcomms (36)
Allergies (147)
Alliances (45224)
ALS (179)
Alzheimer's disease (1766)
Antibody-drug conjugate (ADC) (358)
Approvals (16872)
Artificial intelligence (570)
Autoimmune disease (179)
Automation (36)
Bankruptcy (330)
Best Places to Work (10268)
BIOSECURE Act (23)
Biosimilars (210)
Biotechnology (114)
Bladder cancer (165)
Brain cancer (59)
Breast cancer (639)
Cancer (4930)
Cardiovascular disease (433)
Career advice (2202)
Career pathing (42)
CAR-T (278)
CDC (66)
Celiac Disease (1)
Cell therapy (778)
Cervical cancer (36)
Clinical research (68409)
Collaboration (1731)
Company closure (5)
Compensation (1203)
Complete response letters (78)
COVID-19 (2800)
CRISPR (93)
C-suite (881)
Cystic fibrosis (144)
Data (6281)
Decentralized trials (2)
Denatured (51)
Depression (155)
Diabetes (512)
Diagnostics (6003)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (43)
Drug discovery (269)
Drug pricing (227)
Drug shortages (35)
Duchenne muscular dystrophy (251)
Earnings (74574)
Editorial (69)
Employer branding (20)
Employer resources (152)
Events (101037)
Executive appointments (981)
FDA (19913)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (21)
Funding (1418)
Gene editing (204)
Generative AI (50)
Gene therapy (643)
GLP-1 (1129)
Government (4383)
Grass and pollen (8)
Guidances (382)
Healthcare (16203)
HIV (72)
Huntington's disease (53)
IgA nephropathy (89)
Immunology and inflammation (297)
Immuno-oncology (69)
Indications (123)
Infectious disease (3093)
Inflammatory bowel disease (204)
Inflation Reduction Act (15)
Influenza (121)
Intellectual property (256)
Interviews (480)
IPO (15574)
IRA (59)
Job creations (3886)
Job search strategy (1815)
JPM (72)
Kidney cancer (19)
Labor market (88)
Layoffs (631)
Leadership (43)
Legal (7967)
Liver cancer (95)
Longevity (17)
Lung cancer (664)
Lymphoma (379)
Machine learning (40)
Management (59)
Manufacturing (837)
MASH (175)
Medical device (12035)
Medtech (12085)
Mergers & acquisitions (18489)
Metabolic disorders (1408)
mRNA (193)
Multiple sclerosis (175)
NASH (23)
Neurodegenerative disease (346)
Neuropsychiatric disorders (105)
Neuroscience (3105)
Neurotech (1)
NextGen: Class of 2026 (5594)
Non-profit (3497)
Now hiring (59)
Obesity (703)
Opinion (330)
Ovarian cancer (157)
Pain (211)
Pancreatic cancer (234)
Parkinson's disease (305)
Partnered (29)
Patents (521)
Patient recruitment (517)
Peanut (59)
People (54605)
Pharmaceutical (91)
Pharmacy benefit managers (34)
Phase 1 (21116)
Phase 2 (29731)
Phase 3 (23095)
Pipeline (5666)
Policy (351)
Postmarket research (2618)
Preclinical (8601)
Press Release (50)
Prostate cancer (258)
Psychedelics (59)
Radiopharmaceuticals (289)
Rare diseases (956)
Real estate (5481)
Recruiting (70)
Regulatory (25288)
Reports (45)
Research institute (2305)
Resumes & cover letters (430)
Rett syndrome (28)
RNA editing (18)
RSV (82)
Schizophrenia (162)
Series A (244)
Series B (188)
Service/supplier (14)
Sickle cell disease (107)
Special edition (28)
Spinal muscular atrophy (166)
Sponsored (47)
Startups (3412)
State (2)
Stomach cancer (21)
Supply chain (112)
Tariffs (101)
The Weekly (126)
Vaccines (1138)
Venture capital (97)
Weight loss (491)
Women's health (86)
Worklife (23)
Date
Today (238)
Last 7 days (891)
Last 30 days (2807)
Last 365 days (30071)
2026 (4745)
2025 (30306)
2024 (34087)
2023 (38081)
2022 (48641)
2021 (52459)
2020 (49906)
2019 (40754)
2018 (31140)
2017 (31336)
2016 (30153)
2015 (33898)
2014 (27593)
2013 (23210)
2012 (24848)
2011 (25417)
2010 (23370)
Location
Africa (804)
Alabama (74)
Alaska (7)
Arizona (260)
Arkansas (13)
Asia (40576)
Australia (6532)
California (11229)
Canada (2989)
China (1123)
Colorado (465)
Connecticut (502)
Delaware (342)
Europe (92077)
Florida (1702)
Georgia (338)
Hawaii (4)
Idaho (47)
Illinois (862)
India (71)
Indiana (486)
Iowa (22)
Japan (449)
Kansas (113)
Kentucky (40)
Louisiana (22)
Maine (76)
Maryland (1388)
Massachusetts (8207)
Michigan (283)
Minnesota (593)
Mississippi (5)
Missouri (119)
Montana (20)
Nebraska (26)
Nevada (118)
New Hampshire (68)
New Jersey (3054)
New Mexico (27)
New York (2939)
North Carolina (1490)
North Dakota (7)
Northern California (5552)
Ohio (311)
Oklahoma (17)
Oregon (38)
Pennsylvania (2194)
Puerto Rico (22)
Rhode Island (39)
South America (1175)
South Carolina (65)
South Dakota (1)
Southern California (4388)
Tennessee (164)
Texas (1672)
United States (39684)
Utah (293)
Virginia (276)
Washington D.C. (81)
Washington State (899)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
653,523 Results for "santaris pharma a s formerly pantheco a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
January 12, 2026
·
3 min read
·
Annalee Armstrong
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
February 3, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
February 26, 2026
·
3 min read
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
October 31, 2025
·
3 min read
·
Annalee Armstrong
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
February 11, 2026
·
8 min read
·
Annalee Armstrong
Editorial
Novo Returns to Pre-Wegovy Valuation as Lilly Makes History as First Ever $1T Pharma
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
February 24, 2026
·
3 min read
·
Jef Akst
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
·
2 min read
·
Heather McKenzie
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
1 of 65,353
Next